Editorial: The Non-Coding Transcriptome as a New Player in Intercellular Communication
Yvan Devaux, Florence Pinet, David de Gonzalo-Calvo

To cite this version:
Yvan Devaux, Florence Pinet, David de Gonzalo-Calvo. Editorial: The Non-Coding Transcriptome as a New Player in Intercellular Communication. Frontiers in Molecular Biosciences, 2022, 9, pp.858702. 10.3389/fmolb.2022.858702 . inserm-04023806

HAL Id: inserm-04023806
https://inserm.hal.science/inserm-04023806
Submitted on 10 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Editorial: The Non-Coding Transcriptome as a New Player in Intercellular Communication

Yvan Devaux1†, Florence Pinet2† and David de Gonzalo-Calvo3,4*

1Cardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg, 2Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RId-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées au Vieillissement, Lille, France, 3Translational Research in Respiratory Medicine, University Hospital Arnaud de Villanova and Santa Maria, IRBLleida, Lleida, Spain, 4CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain

Keywords: hormone, communication, microRNA, ncRNA, signal

The Non-Coding Transcriptome as a New Player in Intercellular Communication

Since the discovery of non-coding RNAs (ncRNAs), this family of regulatory RNA molecules has gained great attention as a potential source of clinical indicators, with the number of publications evaluating the translation of circulating ncRNAs as biological markers growing exponentially in the last decade.

Some recent reports illustrate the usefulness of circulating ncRNAs as innovative tools to support medical-decision making in complex conditions (Blanco-Domínguez et al., 2021; Magen et al., 2021; Mens et al., 2021). Paradoxically, the biology of ncRNAs as endocrine genetic signals is far from being completely understood. Evidence from previous in vitro and in vivo studies suggests that ncRNAs may function as intercellular mediators (Cheng et al., 2019; Li et al., 2021). Nevertheless, there are still fundamental gaps that need to be addressed to elucidate the precise role of these molecules as hormone-like mediators (Pinilla et al., 2021). Indeed, the information on mechanisms and pathways implicated in the release/binding of ncRNAs in/to the carriers, target tissue specificity, ncRNAs delivery and the induction of biological responses in the recipient cells is limited. The data on the role of ncRNAs in research fields such as cross-kingdom gene regulation is also scarce (Dávalos et al., 2021). Furthermore, the technical challenges in the isolation of ncRNA carriers, the quantification in biofluids or the evaluation of the endocrine effects in target cells are key limiting factors. Additional studies are fundamental to explore the function of circulating ncRNAs as mediators of physiological and pathological responses. Consequently, the aim of this Research Topic was to promote the investigation on this topic in different diseases such as cancer, metabolic syndrome, respiratory and cardiovascular diseases.

First, Fujimoto et al. discussed the pathological roles and clinical usefulness of vascular microRNAs (miRNAs) contained in endothelial cell-derived EVs (EC-EVs) in respiratory diseases, in particular on chronic obstructive pulmonary disease, pulmonary hypertension and acute respiratory distress syndrome. The results presented suggest the crucial role of EC-EVs on lung homeostasis and how the disruption of the secretory profiles in pathological conditions drives the progression of respiratory diseases and their comorbidities. In the same way, Bartsch et al. presented the most important advances on the role of protein-bound and EV-bound ncRNAs as biomarkers of vascular and valvular diseases and their role as intercellular communicators and regulators of disease pathways. Overall, previous data suggest a strict control of ncRNAs selection and packaging into extracellular carriers and ncRNAs uptake to target cells: from ncRNAs sorting, e.g., the presence of nucleotide sequences in RNAs found in EV (Villarroya-Beltri et al., 2013), to their delivery via specific endocytosis or phagocytosis pathways. Current challenges that should be addressed in the field of ncRNA-based therapeutics include the application method and the mode of transportation. In this scenario, Tapparo et al. evaluated a novel technology to vehicle miRNAs through EVs. Co-incubation emerges as a promising alternative method for the EV cargo enrichment.
maintaining EV integrity and stability. Furthermore, serum EV co-incubation with miR-126 enhanced their pro-angiogenic properties both in vitro and in vivo by increasing the capacity to induce capillary-like structure formation of human EC. These findings were not observed when serum EV were loaded with anti-angiogenic miRNAs, i.e., miR-19b, which supports the selective biological effect mediated by the carried miRNA.

Li et al. explored the role of long non-coding RNAs (lncRNAs) as competing endogenous RNAs (ceRNAs) in metabolic syndrome by analyzing molecular networks in circulating EVs isolated from whole blood. The results showed that metabolic syndrome alters the cargo of circulating EVs and the lncRNA-associated ceRNA network. Importantly, the authors suggested that the ceRNA network within the EVs may play a role in the development and complication of the syndrome, including cancer. In this sense, Wang et al. conducted a comprehensive review of studies on ncRNAs, including miRNAs, lncRNAs and circular RNAs (circRNAs), as regulators of death associated protein kinases (DAPKs) family. Using bioinformatic analyses, the authors described regulatory networks linking ncRNAs and DAPKs which ultimately could be crucial to understand malignant tumor development. Supporting the role of ncRNAs in cancer, Smith et al. reviewed ncRNA molecules that directly or indirectly affect Frizzled protein expression and signaling, receptors implicated in cancer progression. Targeting ncRNAs constitutes an additional approach to inhibiting oncogenic pathways or enhancing tumor-suppressive pathways. Of note, the use of nanoparticles represents an interesting strategy to deliver ncRNA drugs due to the increased stability, circulation time and target accuracy compared to other vectors.

In summary, although previous evidence suggest the potential role of circulating ncRNAs as endocrine genetic signals, further research is still needed to provide a comprehensive overview of the non-coding transcriptome as a determining factor in long-distance signaling. These advances will provide a better understanding of different pathologic conditions, new therapeutic strategies and additional information on biomarkers with clinical application.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**FUNDING**

YD is funded by the EU Horizon 2020 project COVIRNA (Grant Agreement # 101016072), the National Research Fund (grants # C14/BM/8225223, C17/BM/11613033 and COVID-19/2020-1/14719577/miRCOVID), the Ministry of Higher Education and Research, and the Heart Foundation-Daniel Wagner of Luxembourg. FP has received support from the “Fédération Française de Cardiologie”, “Fondation de France”, the French Government, managed by the National Research Agency (ANR) under the program “Investissements d’avenir” with the reference ANR-16-RHU-0003. FP is member of FHU-CARNAVAL. DdG-C has received financial support from Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041), co-funded by the European Social Fund (ESF)/“Investing in your future.” This work is supported by Instituto de Salud Carlos III (PI20/ 00577), co-funded by European Regional Development Fund (ERDF)/”A way to make Europe” and Fundació La Marató de TV3 (202108-30/-31). CIBERS is an initiative of the Instituto de Salud Carlos III. This manuscript is based upon work from EU-CardioRNA COST Action CA17129 (www.cardiorna.eu) supported by COST (European Cooperation in Science and Technology). DdG-C wants particularly to acknowledge Marta Molinero for her technical support.

**REFERENCES**

Blanco-Domínguez, R., Sánchez-Díaz, R., de la Fuente, H., Jiménez-Borreguero, L. J., Matesanz-Marín, A., Relaño, M., et al. (2021). A Novel Circulating MicroRNA for the Detection of Acute Myocarditis. *N. Engl. J. Med.* 384, 2014–2027. doi:10.1056/NEJMOA2003608

Cheng, M., Yang, J., Zhao, X., Zhang, E., Zeng, Q., Yu, Y., et al. (2019). Circulating Myocardial microRNAs from Infarcted Hearts Are Carried in Exosomes and Mobilise Bone Marrow Progenitor Cells. *Nat. Commun.* 10.959 doi:10.1038/S41467-019-08995-7

Dávalos, A., Pinilla, L., López de las Hazas, M.-C., Pinto-Hernández, P., Barbi, F., Iglesias-Gutiérrez, E., et al. (2021). Dietary microRNAs and Cancer: A New Therapeutic Approach. *Sem. in Cancer Biol.* 73, 19–29. doi:10.1016/j.semcancer.2020.10.006

Li, J., Salvador, A. M., Li, G., Valkov, N., Ziegler, O., Yeri, A., et al. (2021). Mir-30d Regulates Cardiac Remodeling by Intrasclerular and Paracrine Signaling. *Circ. Res.* 128, E1–E23. doi:10.1161/CIRCRESAHA.120.317244

Magen, I., Yacovzada, N. S., Yanowsky, E., Coenen-Stass, A., Grosskreutz, J., Lu, C.-H., et al. (2021). Circulating miR-181 Is a Prognostic Biomarker for Amyotrophic Lateral Sclerosis. *Nat. Neurosci.* 24, 1534–1541. doi:10.1038/S41593-021-00936-Z

Mens, M. M. J., Heshmatollah, A., Fani, L., Ikrab, M. A., Ikrab, M. K., and Ghanbari, M. (2021). Circulatory MicroRNA as Potential Biomarkers for Stroke Risk. *Stroke* 52, 945–953. doi:10.1161/STROKEAHA.120.031543

Pinilla, L., Barbé, F., and de Gonzalez-Calvo, D. (2021). MicroRNAs to Guide Medical Decision-Making in Obstructive Sleep Apnea: A Review. *Sleep Med. Rev.* 59, 101458. doi:10.1016/J.SMRV.2021.101458

Villarroya-Beltri, C., Gutiérrez-Vázquez, C., Sánchez-Cabo, F., Pérez-Hernández, D., Vázquez, J., Martin-Cofreces, N., et al. (2013). Sumoylated hnRNP2B1 Controls the Sorting of miRNAs into Exosomes through Binding to Specific Motifs. *Nat. Commun.* 4. doi:10.1038/NCOMMS3980

**Conflict of Interest:** DdGC holds a patent on microRNAs as biomarkers. YD holds patents related to diagnostic and therapeutic applications of RNAs.

FP declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Devaux, Pinet and de Gonzalez-Calvo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.